Treatment of Triple Negative Cell Lines with Olaparib to Block DNA Repair

Area of Science:

• Molecular oncology
• Cancer therapeutics
• Comparative oncology

Background:

• Triple-negative breast cancer (TNBC) is aggressive, with platinum salts like carboplatin as the standard treatment.
• High recurrence rates necessitate novel therapeutic strategies, including Poly (ADP-ribose) polymerase inhibitors (PARPi).
• Olaparib, a PARPi, has shown efficacy in other tumors but requires evaluation in canine mammary tumors.

Purpose of the Study:

• To assess the efficacy of olaparib in inhibiting DNA repair mechanisms in mammary tumor cells.
• To evaluate olaparib's potential to control disease progression by reducing tumor cell migration.
• To investigate the combined effect of olaparib and carboplatin on canine mammary tumor cell lines.

Main Methods:

• Cultured canine (CF41.Mg) and human (MDA-MB-468) mammary tumor cell lines.
• Treated cells with carboplatin, olaparib, or a combination, assessing cell viability via MTT assay.
• Evaluated PARP-1 expression (protein and gene) using immunofluorescence, Western blotting, and qRT-PCR.
• Quantified cell migration and invasion using Transwell chambers.

Main Results:

• Carboplatin and olaparib treatments significantly decreased PARP-1 expression in both cell lines compared to controls (p<0.05).
• Both agents, individually and in combination, markedly reduced the invasion rate of mammary tumor cells (p<0.05).
• The combination therapy demonstrated potent inhibition of DNA repair and cancer cell invasion.

Conclusions:

• Carboplatin and olaparib effectively inhibit DNA repair and control cancer invasion, particularly when used together.
• Olaparib shows significant potential as a therapeutic agent for canine mammary tumors.
• The findings suggest olaparib could be a valuable treatment option for both human and canine breast cancers.